Table of Contents Author Guidelines Submit a Manuscript
Advances in Hematology
Volume 2017, Article ID 6527306, 9 pages
https://doi.org/10.1155/2017/6527306
Research Article

Sp17 Protein Expression and Major Histocompatibility Class I and II Epitope Presentation in Diffuse Large B Cell Lymphoma Patients

1Nuffield Division of Clinical Laboratory Sciences, Radcliffe Department of Medicine, University of Oxford, Oxford, UK
2Transplant Immunology & Immunogenetics, Oxford Transplant Centre, Churchill Hospital, Oxford, UK
3Department of Clinical Haematology, Churchill Hospital, Oxford, UK

Correspondence should be addressed to Karen Pulford; ku.ca.xo.slcdn@droflup.nerak

Received 30 July 2017; Accepted 12 September 2017; Published 24 October 2017

Academic Editor: Shaji Kumar

Copyright © 2017 Kamel Ait-Tahar et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Supplementary Material

Supplementary Table 1: Summary of the characterisics of the DLBCL cases investigated here. Patients presented with differing stages and subtype of disease. Their clinical details, treatment protocols and survival status are also listed. Supplementary Table 2: Summary of cytotoxic T lymphocyte (CTL) and CD4 responses to Sp17 and PASD1. Cells from ten patients were able to mount CTL responses to both the Sp17 and PASD1 cancer testis antigens. CD4 Th responses to both the PASD1 and Sp17 antigens were also detected in five of these patients.

  1. Supplementary Material